Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist

https://doi.org/10.1016/j.bmcl.2011.02.090Get rights and content

Abstract

We report the discovery of piperazine urea based compound 1, a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Compound 1 shows anti-obesity efficacy without potentiating erectile activity in the rodent models.

Graphical abstract

We report the discovery of piperazine urea based compound 1, a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Compound 1 shows anti-obesity efficacy without potentiating erectile activity in the rodent models.

  1. Download : Download full-size image

References and notes (35)

  • W.J. Martin et al.

    Eur. Urol.

    (2004)
  • A.S. Garfield et al.

    Trends Endocrinol. Metab.

    (2009)
  • I. Sebhat et al.

    Annu. Rep. Med. Chem.

    (2003)
  • D.J. MacNeil et al.

    Eur. J. Pharmacol.

    (2002)
  • C. Chen

    Prog. Med. Chem.

    (2007)
  • B.L. Palucki et al.

    Bioorg. Med. Chem. Lett.

    (2005)
  • F. Ujjainwalla et al.

    Bioorg. Med. Chem. Lett.

    (2005)
  • S. He et al.

    Bioorg. Med. Chem. Lett.

    (2010)
  • J.A. Tran et al.

    Bioorg. Med. Chem. Lett.

    (2007)
  • W. Jiang et al.

    Bioorg. Med. Chem. Lett.

    (2007)
  • C.W. Chen et al.

    Bioorg. Med. Chem. Lett.

    (2007)
  • C. Chen et al.

    Bioorg. Med.Chem. Lett.

    (2008)
  • M.A. Bednarek et al.

    Peptides

    (1999)
  • Ira Gantz et al.

    Am. J. Physiol. Endocrinol. Metab.

    (2003)
  • J.R. Holder et al.

    Med. Res. Rev.

    (2004)
  • R.D. Cone

    Endocrinol. Rev.

    (2006)
  • A. Catania et al.

    Pharmacol. Rev.

    (2004)
  • Cited by (13)

    • Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016

      2017, Biochimica et Biophysica Acta - Molecular Basis of Disease
      Citation Excerpt :

      A 200 mg dose demonstrated similar efficacy to sildenafil and demonstrated a significant effect compared to the placebo control [137]. As a final small molecule for the MC4R derived from the MB243 scaffold, the Merck group incorporated a substituted piperazine attached through a urea linkage while preserving the halogenated aromatic ring and tert-buyl/cyclohexyl substituted piperidine of MB243 (14, Fig. 3) [160]. This series was designed to partially activate the receptor with the aims of decreasing food intake while not inducing an erectile response.

    • New targets to treat obesity and the metabolic syndrome

      2015, European Journal of Pharmacology
      Citation Excerpt :

      A major disadvantage of most MC4R agonists is their poor bioavailability. A piperazine-based highly specific partial MC4R agonist has been shown to have good oral bioavailability in rat (Hong et al., 2011). It reduces food intake by almost 40%.

    • Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents

      2015, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Compound 137 was the most potent compound, both in terms of binding and functional activity [235]. Among the various piperazine analogs developed by Hong et al., compound 138 displayed potent anti-obesity activity [236]. Psychosis, a distorted mental state is characterized by delusions, hallucinations, disorganized speech and behavior [237].

    • Are GPCRs still a source of new targets?

      2013, Journal of Biomolecular Screening
    • Synthesis, spectroscopic, structural and conformational study of some tri-substituted ureas derived from N-methylpiperazine containing phenyl and N-heterocyclic substituents

      2013, Journal of Molecular Structure
      Citation Excerpt :

      Substituted piperazines are common motifs in a large number of compounds with biological activity. Specifically, N-urea and N,N′-bis-urea piperazine derivatives have interesting therapeutic indications [1–3]. Furthermore, thiazole and benzothiazole derivatives are widely used in the synthesis of medicinal compounds [4].

    View all citing articles on Scopus
    View full text